

Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029

<https://marketpublishers.com/r/G416833BDB0EEN.html>

Date: November 2023

Pages: 1800

Price: US\$ 5,100.00 (Single User License)

ID: G416833BDB0EEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029
Reports Findings & Highlights:

Global Peptide Therapeutics Market Opportunity: > USD 80 Billion By 2029

Global & Regional Peptide Therapeutics Market Outlook

Insight On Peptides In Clinical Trials By Country, Indication & Phase: > 900
Peptides In Trials

Comprehensive Insight On Peptides Drugs Available in Market: > 200 Peptides

Marketed Peptide Drugs Insight: Patent, Availability, Cost, Dosage, & Sales
Insight

Global, Regional, Annual & Quarterly Sales Insights

Peptide Therapeutics Development Technologies Platform

Global Peptide Drugs Clinical Research & Market Trends by Indication

In the dynamic pharmaceutical landscape, peptide drugs stand out as an indicator of innovation and therapeutic potential. These exception therapeutic agents have received

a lot of interest due to their wide range of applications and distinct advantages. Peptide drugs provide a precise and personalized approach to therapy, from treating metabolic abnormalities to tackling complex diseases like cancer. As a result, it has become important for the pharmaceutical industry to understand the growing significance of peptides in the market to exploit their full potential, and also the revolutionary influence they are poised to have in the constantly evolving environment of healthcare.

Once overshadowed by small molecule and large protein based therapeutics, peptides have emerged as the new growth frontier of the pharmaceutical realm in the recent years. They have demonstrated therapeutic, diagnostic and theranostic properties, ushering in a new era of precision medicine. These adaptable molecules serve a critical role in treating a wide range of medical conditions by providing targeted therapeutic interventions. Beyond their treatment prowess, peptides illuminate the diagnostic landscape, serving as beacons in the detection of specific biomarkers and diseases. The convergence of therapeutic and diagnostic capabilities gives rise to the evolutionary concept of theranostics, where peptides act as both healers and guides, navigating the path toward personalized and effective healthcare solutions.

The continuous evolution of peptide drug development is fuelled by advancements in research and technology. Combinatorial chemistry and high-throughput screening have aided in the discovery of new peptide sequences with medicinal promise. Furthermore, advances in peptide synthesis processes have increased manufacturing efficiency, addressing historical issues with scalability and cost-effectiveness. The integration of computational tools and structure biology in peptide design has sped up the identification of lead compounds, reducing the time required for drug development.

The incorporation of artificial intelligence in peptide drug development has ushered in a new era of efficiency and innovation. Machine learning algorithms analyze vast datasets, predicting peptide structures with high binding affinities and enhancing the success rate of drug candidates. Additionally, AI helps in the identification of potential adverse events and optimization of pharmacokinetic properties, contributing to the overall quality of peptide therapeutics. Pharmaceutical companies such as ProteinQure have developed an extensive portfolio of peptide therapeutics using computational tools, while others like Space Peptides provide contract services to grant access to their machine learning and AI tools to design and produce premium peptide drugs.

The escalating interest of large pharmaceutical companies in peptide drugs is evident from the rapidly expanding global pipeline of peptide therapeutics. In addition, a surge

of collaborations and strategic partnerships has been observed in the recent months within the pharmaceutical industry, some of these involving prominent pharmaceutical companies including Eli Lilly and AstraZeneca. Recognizing the potential of peptides to address unmet medical needs, prominent companies are aggressively seeking to expand their peptide portfolios through joint ventures, licensing agreements and acquisitions, which allow resource pooling and utilization of combined knowledge, thereby accelerating the development and commercialization of peptide drugs.

Peptide drugs are expected to play a significant role in the future landscape of the global pharmaceutical market. The growing understanding of disease causes at molecular levels coincides with the precision targeting abilities of peptides, making them a cornerstone in personalized medicine. Continuous advances in peptide engineering, together with the incorporation of AI, will almost certainly result in the development of highly effective and well-tolerated treatments. As the pharmaceutical industry move toward patient-centric paradigm, the adaptability and specificity of peptide drugs positions them as frontrunners in addressing the shifting healthcare landscape. Peptides' adaptability across therapeutic areas, paired with their good safety rating, makes them an appealing choice for pharmaceutical companies seeking to fulfil patients' medical diverse needs.

In conclusion, the journey through the realm of peptide drugs reveals an extensive array of innovation and potential. As we approach a new era in pharmaceuticals, peptides appear as more than merely therapeutic and diagnostic agents, but also as forerunners of a paradigm shift in healthcare. Peptides will play a crucial role in personalized medicine, targeted therapeutics, and the ever-expanding panorama of precision healthcare in the future. The combination of cutting-edge technology like AI with the inherent versatility of peptides opens the door to exceptional developments. The expanding peptide drugs narrative paints a captivating vision of a future in which these molecules continue to push the bounds of medical possibility, delivering innovative treatments and optimisms on the horizon.

Contents

1. INTRODUCTION TO PEPTIDE DRUGS

- 1.1 History, Development & Evolution
- 1.2 Approved Peptide Drugs

2. PEPTIDE DRUGS – THERAPEUTIC, DIAGNOSTIC & THERANOSTIC POTENTIAL & MARKET IMPLICATIONS

- 2.1 Therapeutic Potential & Market Implications
- 2.2 Diagnostic Potential & Market Implications
- 2.3 Theranostic Potential & Market Implications

3. GLOBAL PEPTIDE DRUGS CLINICAL RESEARCH & MARKET TRENDS BY INDICATION

- 3.1 Inheritable Genetic Diseases
- 3.2 Cancer
- 3.3 Microbial Infections
- 3.4 Autoimmune Disorders
- 3.5 Metabolic Disorders
- 3.6 Neurodegenerative Diseases

4. PEPTIDE BASED THERAPEUTIC APPROACHES

- 4.1 Peptide Hormone Drugs
- 4.2 Peptide Drug Conjugates
- 4.3 Peptide Vaccines
- 4.4 Peptide Agonists
- 4.5 Peptide Aptamers
- 4.6 Peptide Antibody

5. GLOBAL PEPTIDE THERAPEUTICS MARKET OUTLOOK

- 5.1 Current Market Trends & Drivers
- 5.2 Future Growth Avenues

6. PEPTIDE THERAPEUTICS MARKET LANDSCAPE BY REGION

- 6.1 US
- 6.2 EU
- 6.3 China
- 6.4 Japan
- 6.5 South Korea
- 6.6 UK
- 6.7 India
- 6.8 Middle East
- 6.9 Canada
- 6.10 Australia

7. GLOBAL PEPTIDE THERAPEUTICS CLINICAL TRIALS OVERVIEW

- 7.1 By Country
- 7.2 Indication
- 7.3 Phase
- 7.4 Priority Status
- 7.5 Therapy Class

8. MARKETED PEPTIDE DRUGS INSIGHT – PATENT, AVAILABILITY, COST, DOSAGE, & SALES INSIGHT

- 8.1 Bylvay
 - 8.1.1 Overview
 - 8.1.2 Pricing & Dosage Analysis
 - 8.1.3 Sales Insight
- 8.2 Parsabiv
 - 8.2.1 Overview & PatentS Insight
 - 8.2.2 Pricing & Dosage Analysis
 - 8.2.3 Sales Insight
- 8.3 Bydureon BCise
 - 8.3.1 Overview & Patent Insight
 - 8.3.2 Pricing & Dosage Analysis
 - 8.3.3 Sales Insight
- 8.4 Linzess
 - 8.4.1 Overview & Patent Insight
 - 8.4.2 Pricing & Dosage Insight
 - 8.4.3 Sales Insight

8.5 Increlex

- 8.5.1 Overview & Patent Insight
- 8.5.2 Pricing & Dosage Insight
- 8.5.3 Sales Analysis

8.6 Terlivaz

- 8.6.1 Overview & Patent Insight
- 8.6.2 Pricing & Dosage Insight
- 8.6.3 Sales Analysis

8.7 Empaveli

- 8.7.1 Overview & Patent Insight
- 8.7.2 Pricing & Dosage Insight
- 8.7.3 Sales Analysis

8.8 Voxzogo

- 8.8.1 Overview & Patent Insight
- 8.8.2 Pricing & Dosage Insight
- 8.8.3 Sales Analysis

8.9 Incivree

- 8.9.1 Overview & Patent Insight
- 8.9.2 Pricing & Dosage Insight
- 8.9.3 Sales Analysis

8.10 Trulicity

- 8.10.1 Overview & Patent Insight
- 8.10.2 Pricing & Dosage Insight
- 8.10.3 Sales Analysis

8.11 Ozempic

- 8.11.1 Overview & Patent Insight
- 8.11.2 Pricing & Dosage Insight
- 8.11.3 Sales Analysis

8.12 Wegovy

- 8.12.1 Overview & Patent Insight
- 8.12.2 Pricing & Dosage Insight
- 8.12.3 Sales Analysis

8.13 Tresiba

- 8.13.1 Overview & Patent Insight
- 8.13.2 Pricing & Dosage Insight
- 8.13.3 Sales Analysis

8.14 Rybelsus

- 8.14.1 Overview & Patent Insight
- 8.14.2 Pricing & Dosage Insight

- 8.14.3 Sales Analysis
- 8.15 Xultophy
 - 8.15.1 Overview & Patent Insight
 - 8.15.2 Pricing & Dosage Insight
 - 8.15.3 Sales Analysis
- 8.16 Victoza
 - 8.16.1 Overview & Patent Insight
 - 8.16.2 Pricing & Dosage Insight
 - 8.16.3 Sales Analysis
- 8.17 Ryzodeg
 - 8.17.1 Overview & Patent Insight
 - 8.17.2 Pricing & Dosage Insight
 - 8.17.3 Sales Analysis
- 8.18 Fiasp
 - 8.18.1 Overview & Patent Insight
 - 8.18.2 Pricing & Dosage Insight
 - 8.18.3 Sales Analysis
- 8.19 Lantus
 - 8.19.1 Overview & Patent Insight
 - 8.19.2 Pricing & Dosage Insight
 - 8.19.3 Sales Analysis
- 8.20 Toujeo
 - 8.20.1 Overview & Patent Insight
 - 8.20.2 Pricing & Dosage Insight
 - 8.20.3 Sales Analysis

9. PEPTIDE THERAPEUTICS DEVELOPMENT TECHNOLOGIES PLATFORM

- 9.1 Biodrug Design Accelerator - Fujitsu/PeptiDream
- 9.2 T-Win® Technology - IO Biotech
- 9.3 Numatech – Numaferm
- 9.4 ProteinStudio – ProteinQure
- 9.5 The Magnifier N??™ - Nuritas
- 9.6 PepPower – GenScript
- 9.7 Unnamed Peptide Platform - Zealand Pharma
- 9.8 PDPS (Peptide Discovery Platform System) - PeptiDream
- 9.9 Veneno Suite - Veneno Technologies
- 9.10 SmartDepot™ Technology - Peptron
- 9.11 Bicycles - Bicycle Therapeutics

- 9.12 RALA Technolgy - pHion Therapeutics
- 9.13 Discovery Platform - Orbit Discovery
- 9.14 Imotopes – Imcyse
- 9.15 Nautilus - Peptilogics
- 9.16 Swarm Intelligence 2.0 – Pepticom
- 9.17 streaMLine Platform – Gubra
- 9.18 Precision Endocrine Peptides (PEPs) - MBX Biosciences
- 9.19 pHLIP (pH-Low Insertion Peptides) - pHLIP
- 9.20 alphalex – Cybrexa

10. CYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

- 10.1 Research
- 10.2 Preclinical
- 10.3 Phase-I
- 10.4 Phase-I/II
- 10.5 Phase-II
- 10.6 Phase-II/III
- 10.7 Phase-III
- 10.8 Preregistration
- 10.9 Registered
- 10.10 Marketed

11. PEPTIDE HORMONES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

- 11.1 Research
- 11.2 Preclinical
- 11.3 Phase-I
- 11.5 Phase-I/II
- 11.6 Phase-II
- 11.7 Phase-II/III
- 11.8 Phase-III
- 11.9 Preregistration
- 11.10 Registered
- 11.11 Marketed

12. PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

- 12.1 Research
- 12.2 Preclinical
- 12.3 Phase-I
- 12.4 Phase-I/II
- 12.5 Phase-II
- 12.6 Phase-II/III
- 12.7 Phase-III
- 12.8 Preregistration
- 12.9 Registered
- 12.10 Marketed

13. GLUCAGON-LIKE PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

- 13.1 Preclinical
- 13.2 Phase-I
- 13.3 Phase-I/II
- 13.4 Phase-II
- 13.5 Phase-III
- 13.6 Marketed

14. OLIGOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

- 14.1 Research
- 14.2 Preclinical
- 14.3 Phase-I
- 14.4 Phase-I/II
- 14.5 Phase-II
- 14.6 Phase-II/III
- 14.7 Phase-III
- 14.8 Registered
- 14.9 Marketed

15. LIPOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

- 15.1 Research

15.2 Preclinical

15.3 Phase-II

15.4 Marketed

16. DIPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

16.1 Research

16.2 Preclinical

16.3 Phase-I

16.4 Phase-II

16.5 Phase-III

16.6 Registered

16.7 Marketed

17. DEPSIPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

17.1 Preclinical

17.2 Phase-I

17.3 Phase-II

17.4 Marketed

18. GLYCOPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

18.1 Preclinical

18.2 Phase-I

18.3 Phase-I/II

18.5 Phase-II

18.6 Phase-III

18.8 Marketed

19. PEPTIDE VACCINES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

19.1 Preclinical

19.2 Phase-I/II

19.3 Phase-II

19.4 Phase-III

19.5 Registered

19.6 Marketed

20. PEPTIDE FRAGMENTS CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

20.1 Preclinical

20.2 Phase-I

20.3 Phase-II

20.4 Phase-III

20.5 Preregistration

20.6 Registered

20.7 Marketed

21. OPIOID PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

21.1 Research

21.2 Preclinical

21.3 Phase-I

21.4 Phase-II

21.5 Preregistration

21.6 Registered

21.7 Marketed

22. NATRIURETIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

22.1 Preclinical

22.2 Phase-I

22.3 Phase-II

22.4 Phase-II/III

22.5 Phase-III

22.6 Marketed

23. NEUROPEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

23.1 Research

23.2 Preclinical

23.3 Phase-I

23.4 Phase-I/II

23.5 Phase-II

23.6 Marketed

24. ANTIMICROBIAL CATIONIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

24.1 Preclinical

24.2 Phase-I

24.3 Phase-III

25. PEPTIDE HYDROLASES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

25.1 Phase-II

26. PEPTIDE APTAMERS

26.1 Research

26.2 Preclinical

26.3 Phase-I

26.4 Phase-II

27. INTERCELLULAR SIGNALLING PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

27.1 Phase-II

28. PEPTIDE ANTIBIOTICS CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

28.1 Phase-I

29. PEPTIDE DRUG CONJUGATES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

29.1 Preclinical

30. BICYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

30.1 Preclinical

31. MULTIPLE PEPTIDES CLINICAL TRIALS INSIGHT BY COUNTRY, INDICATION & PHASE

31.1 Research

31.2 Preclinical

31.3 Phase-I

31.4 Phase-I/II

31.5 Phase-II

31.6 Preregistration

31.7 Registered

31.8 Marketed

32. COMPETITIVE LANDSCAPE

32.1 AbbVie

32.2 Adocia

32.3 Amgen

32.4 Antlia Bioscience

32.5 AsclepiX Therapeutics

32.6 AstraZeneca

32.7 Bicycle Therapeutics

32.8 Biohaven Labs

32.9 Bristol-Myers Squibb

32.10 Carmot Therapeutics

32.11 Eli Lilly and Company

32.12 Ferring Pharmaceuticals

32.13 Gan&Lee Pharmaceuticals

32.14 GEROPHARM

32.15 Hanmi Pharmaceutical

32.16 HEC Pharm

32.17 Heidelberg Pharma AG

32.18 ImCyse

32.19 Janux Therapeutics

- 32.20 Kine Sciences
- 32.21 Lactocore
- 32.22 Maxwell Biosciences
- 32.23 Merck & Co
- 32.24 Novartis
- 32.25 Novo Nordisk
- 32.26 Oryn Therapeutics
- 32.27 Palatin Technologies
- 32.28 PeptiDream
- 32.29 Pfizer
- 32.30 Priavoid
- 32.31 Primary Peptides
- 32.32 Protagonist Therapeutics
- 32.33 Roche
- 32.34 Sanofi
- 32.35 Sapience Therapeutics
- 32.36 Seagen
- 32.37 Shaanxi Micot Technology Co
- 32.38 Stuart Therapeutics
- 32.39 Takeda
- 32.40 Zealand Pharma

12. LIST OF FIGURES

- Figure 1-1: Landmarks in Peptides Drugs Market
- Figure 3-1: Pro00013585 Phase II Study – Initiation & Completion Years
- Figure 3-2: STUDY0000567 Phase II Study – Initiation & Completion Years
- Figure 3-3: NCT05378672 Phase III Study – Initiation & Completion Years
- Figure 3-4: ZP4207-21052 Phase III Study – Initiation & Completion Years
- Figure 3-5: GLSI-21-01 Phase III Study – Initiation & Completion Years
- Figure 3-6: IO102-IO103-013 Phase III Study – Initiation & Completion Years
- Figure 3-7: NCT06091748 Phase II Study – Initiation & Completion Years
- Figure 3-8: PMC67199 Phase I Study – Initiation & Completion Years
- Figure 3-9: ACW-1221958-1 Phase II Study – Initiation & Completion Years
- Figure 3-10: NCT05841095 Phase I/II Study – Initiation & Completion Years
- Figure 3-11: NCT05340790 Phase I Study – Initiation & Completion Years
- Figure 3-12: IR902-007 Phase I Study – Initiation & Completion Years
- Figure 3-13: ISEMIS Phase I/II Study – Initiation & Completion Years
- Figure 3-14: YN011-301 Phase II/III Study – Initiation & Completion Years

- Figure 3-15: SCW0502-1031 Phase III Study – Initiation & Completion Years
Figure 3-16: NCT05202353 Phase I Study – Initiation & Completion Years
Figure 3-17: NCT04305002 Phase II Study – Initiation & Completion Years
Figure 3-18: NCT05189210 Phase II Study – Initiation & Completion Years
Figure 3-19: ALZ-C-001 Phase II Study – Initiation & Completion Years
Figure 3-20: ELViS-FA Phase I/II Study – Initiation & Completion Years
Figure 3-21: NCT05634876 Phase II Study – Initiation & Completion Years
Figure 4-1: CUV104 Phase II Study – Initiation & Completion Years
Figure 4-2: CUV152 Phase II Study – Initiation & Completion Years
Figure 4-3: Peptide-Drug Conjugate Structure
Figure 4-4: NCT04706962 Phase I Study – Initiation & Completion Years
Figure 4-5: MLB-PK-001 Early Phase I Study – Initiation & Completion Year
Figure 4-6: ANGLEd Phase III Study – Initiation & Completion Years
Figure 4-7: CA209-8TX Phase I/II Study – Initiation & Completion Years
Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study – Initiation & Completion Years
Figure 4-9: COVENANT Phase III Study – Initiation & Completion Years
Figure 4-10: EGRABIS1 Phase II Study – Initiation & Completion Years
Figure 4-11: GLIMP Phase II Study – Initiation & Completion Years
Figure 4-12: NCT05530577 Phase II Study – Initiation & Completion Years
Figure 5-1: Global – Peptide Therapeutic Market Size (US\$ Billion), 2022 - 2029
Figure 5-2: Global – Peptide Oncology Drugs Market Size (US\$ Billion), 2022 - 2029
Figure 5-3: Ongoing Trends in Peptide Drugs Market
Figure 5-4: Future Growth Avenues in Peptide Drugs Market
Figure 6-1: China – Estimated Diabetes Population (Million), 2021 & 2030
Figure 6-2: India – Estimated Diabetes Population (Million), 2021 & 2030
Figure 6-3: ME – Estimated Diabetes Population in Saudi Arabia & UAE (Million), 2021 & 2030
Figure 6-4: Canada – Estimated Diabetes Population (Million), 2021 & 2030
Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
Figure 7-3: Global – Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-4: Global – Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-5: Global – Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till

2029

- Figure 7-6: Global – Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
Figure 7-7: Global – Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029

Figure 7-8: Global – Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029

Figure 7-9: Global – Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029

Figure 7-10: Global – Depsipeptides Clinical Trials by Phase (Numbers), 2023 till

2029

Figure 7-11: Global – Glycopeptides Clinical Trials by Phase (Numbers), 2023 till

2029

Figure 7-12: Global – Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till

2029

Figure 7-13: Global – Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till
2029

Figure 7-14: Global – Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till

2029

Figure 7-15: Global – Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023
till 2029

Figure 7-16: Global – Neuropeptides Clinical Trials by Phase (Numbers), 2023 till

2029

Figure 7-17: Global – Antimicrobial Cationic Peptides Clinical Trials by Phase
(Numbers), 2023 till 2029

Figure 7-18: Global – Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till

2029

Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till

2029

Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till

2029

Figure 8-1: US – Cost per Unit & Supply of Bylvay Oral Capsules (US\$),
November'2023

Figure 8-2: US – Cost per Unit & Supply of Bylvay Oral Pellets (US\$), November'2023

Figure 8-3: EU – Cost per Unit & Supply of Bylvay Oral Capsules & Pellets (Eur/US\$),
November'2023

Figure 8-4: Global – Quarterly Bylvay Sales (US\$ Million), 2023

Figure 8-5: NA – Quarterly Bylvay Sales (US\$ Million), 2023

Figure 8-6: Europe – Quarterly Bylvay Sales (US\$ Million), 2023

Figure 8-7: ROW – Quarterly Bylvay Sales (US\$ Million), 2023

Figure 8-8: Parsabiv – US Patents Expiration Years

Figure 8-9: Parsabiv – Europe Patents Expiration Years

Figure 8-10: Parsabiv – Cost per Unit & Supply (US\$), November'2023

Figure 8-11: Global – Annual Parsabiv Sales (US\$ Million), 2019-2023

Figure 8-12: US – Annual Parsabiv Sales (US\$ Million), 2019-2023

Figure 8-13: ROW – Annual Parsabiv Sales (US\$ Million), 2019-2023

Figure 8-14: Global – Quarterly Parsabiv Sales (US\$ Million), 2023

Figure 8-15: US – Quarterly Parsabiv Sales (US\$ Million), 2023

Figure 8-16: ROW – Quarterly Parsabiv Sales (US\$ Million), 2023

Figure 8-17: Global – Quarterly Parsabiv Sales (US\$ Million), 2022

Figure 8-18: US – Quarterly Parsabiv Sales (US\$ Million), 2022

Figure 8-19: ROW – Quarterly Parsabiv Sales (US\$ Million), 2022

Figure 8-20: Bydureon – Year of Approval and Expiry of Patents for Injection

Figure 8-21: Bydureon – Year of Approval and Expiry of Patents for Injection

Figure 8-22: Bydureon BCise – Cost per Unit & Supply (US\$), November'2023

Figure 8-23: Global – Annual Bydureon Sales (US\$ Million), 2019-2023

Figure 8-24: US – Annual Bydureon Sales (US\$ Million), 2019-2023

Figure 8-25: Europe – Annual Bydureon Sales (US\$ Million), 2019-2023

Figure 8-26: EM – Annual Bydureon Sales (US\$ Million), 2019-2023

Figure 8-27: ROW – Annual Bydureon Sales (US\$ Million), 2019-2023

Figure 8-28: Global – Quarterly Bydureon Sales (US\$ Million), 2023

Figure 8-29: US – Quarterly Bydureon Sales (US\$ Million), 2023

Figure 8-30: Europe – Quarterly Bydureon Sales (US\$ Million), 2023

Figure 8-31: EM – Quarterly Bydureon Sales (US\$ Million), 2023

Figure 8-32: Global – Quarterly Bydureon Sales (US\$ Million), 2022

Figure 8-33: US – Quarterly Bydureon Sales (US\$ Million), 2022

Figure 8-34: Europe – Quarterly Bydureon Sales (US\$ Million), 2022

Figure 8-35: EM – Quarterly Bydureon Sales (US\$ Million), 2022

Figure 8-36: Linzess – Cost per Unit & Supply (US\$), November'2023

- Figure 8-37: Linzess – Dosage by Indication (mcg)
- Figure 8-38: Global – Annual Linzess Sales (US\$ Million), 2020-2023
- Figure 8-39: US – Annual Linzess Sales (US\$ Million), 2020-2023
- Figure 8-40: ROW – Annual Linzess Sales (US\$ Million), 2019-2023
- Figure 8-41: Global – Quarterly Linzess Sales (US\$ Million), 2023
- Figure 8-42: US – Quarterly Linzess Sales (US\$ Million), 2023
- Figure 8-43: ROW – Quarterly Linzess Sales (US\$ Million), 2023
- Figure 8-44: Global – Quarterly Linzess Sales (US\$ Million), 2022
- Figure 8-45: US – Quarterly Linzess Sales (US\$ Million), 2022
- Figure 8-46: ROW – Quarterly Linzess Sales (US\$ Million), 2022
- Figure 8-47: Increlex – US & EU Patent Expiry Years
- Figure 8-48: Increlex – Cost per Unit & Supply (US\$), November'2023
- Figure 8-49: Global – Annual Increlex Sales (US\$ Million), 2019-2023
- Figure 8-50: Global – Quarterly Increlex Sales (US\$ Million), 2023
- Figure 8-51: Global – Quarterly Increlex Sales (US\$ Million), 2022
- Figure 8-52 : Terlivaz - Dosing Chart
- Figure 8-53: Global – Quarterly Terlivaz Sales (US\$ Million), 2023
- Figure 8-54: Empaveli – Cost per Unit & Supply (US\$), November'2023
- Figure 8-55: Empaveli – Cost of Monthly & Yearly Treatment (US\$), November'2023
- Figure 8-56: Global – Annual Empaveli Sales (US\$ Million), 2021-2023
- Figure 8-57: US – Annual Empaveli Sales (US\$ Million), 2021-2023
- Figure 8-58: ROW – Annual Empaveli Sales (US\$ Million), 2021-2023
- Figure 8-59: Global – Quarterly Increlex Sales (US\$ Million), 2023
- Figure 8-60: US – Quarterly Empaveli Sales (US\$ Million), 2023
- Figure 8-61: ROW – Quarterly Empaveli Sales (US\$ Million), 2023
- Figure 8-62: Global – Quarterly Increlex Sales (US\$ Million), 2022
- Figure 8-63: US – Annual Empaveli Sales (US\$ Million), 2022
- Figure 8-64: ROW – Annual Empaveli Sales (US\$ Million), 2022
- Figure 8-65: Voxzogo – Cost per Unit & Supply (US\$), November'2023
- Figure 8-66: Global – Annual Voxzogo Sales (US\$ Million), 2021-2023
- Figure 8-67: Global – Quarterly Voxzogo Sales (US\$ Million), 2023
- Figure 8-68: Global – Quarterly Voxzogo Sales (US\$ Million), 2022
- Figure 8-69: Global – Annual Imcivree Sales (US\$ Million), 2021-2023
- Figure 8-70: Global – Quarterly Imcivree Sales (US\$ Million), 2023
- Figure 8-71: Global – Quarterly Imcivree Sales (US\$ Million), 2022
- Figure 8-72: Voxzogo – Cost per Unit & Supply (US\$), November'2023
- Figure 8-73: Global – Annual Trulicity Sales (US\$ Million), 2019-2023
- Figure 8-74: Global – Quarterly Trulicity Sales (US\$ Million), 2023
- Figure 8-75: Global – Quarterly Trulicity Sales (US\$ Million), 2022

- Figure 8-76: Ozempic – Cost per Unit & Supply (US\$), November'2023
- Figure 8-77: Ozempic – Initiation and Increment Doses (mg/week)
- Figure 8-78: Global – Annual Ozempic Sales (US\$ Million), 2019-2023
- Figure 8-79: NA – Annual Ozempic Sales (US\$ Million), 2019-2023
- Figure 8-80: EMEA – Annual Ozempic Sales (US\$ Million), 2019-2023
- Figure 8-81: China – Annual Ozempic Sales (US\$ Million), 2019-2023
- Figure 8-82: ROW – Annual Ozempic Sales (US\$ Million), 2019-2023
- Figure 8-83: Global – Quarterly Ozempic Sales (US\$ Million), 2023
- Figure 8-84: NA – Quarterly Ozempic Sales (US\$ Million), 2023
- Figure 8-85: EMEA – Quarterly Ozempic Sales (US\$ Million), 2023
- Figure 8-86: China – Quarterly Ozempic Sales (US\$ Million), 2023
- Figure 8-87: ROW – Quarterly Ozempic Sales (US\$ Million), 2023
- Figure 8-88: Global – Quarterly Ozempic Sales (US\$ Million), 2022
- Figure 8-89: NA – Quarterly Ozempic Sales (US\$ Million), 2022
- Figure 8-90: EMEA – Quarterly Ozempic Sales (US\$ Million), 2022
- Figure 8-91: China – Quarterly Ozempic Sales (US\$ Million), 2022
- Figure 8-92: ROW – Quarterly Ozempic Sales (US\$ Million), 2022
- Figure 8-93: Wegovy – Cost per Unit & Supply of 0.25mg, 0.5mg and 1mg Solutions (US\$), November'2023
- Figure 8-94: Wegovy – Cost per Unit & Supply of 1.7mg, and 2.4mg Solutions (US\$), November'2023
- Figure 8-95: Global – Annual Wegovy Sales (US\$ Million), 2021-2023
- Figure 8-96: NA – Annual Wegovy Sales (US\$ Million), 2021-2023
- Figure 8-97: EMEA – Annual Wegovy Sales (US\$ Million), 2021-2023
- Figure 8-98: Global – Quarterly Wegovy Sales (US\$ Million), 2023
- Figure 8-99: NA – Quarterly Wegovy Sales (US\$ Million), 2023
- Figure 8-100: EMEA – Quarterly Wegovy Sales (US\$ Million), 2023
- Figure 8-101: Global – Quarterly Wegovy Sales (US\$ Million), 2022
- Figure 8-102: NA – Quarterly Wegovy Sales (US\$ Million), 2022
- Figure 8-103: EMEA – Quarterly Wegovy Sales (US\$ Million), 2022
- Figure 8-104: Tresiba – Cost per Unit & Supply of 100 units/mL Solution (US\$), November'2023
- Figure 8-105: Tresiba – Cost per Unit & Supply of 200 units/mL Solution (US\$), November'2023
- Figure 8-106: Insulin degludec – Cost per Unit & Supply of 100 units/mL Solution (US\$), November'2023
- Figure 8-107: Global – Annual Tresiba Sales (US\$ Million), 2019-2023
- Figure 8-108: NA – Annual Tresiba Sales (US\$ Million), 2019-2023
- Figure 8-109: EMEA – Annual Tresiba Sales (US\$ Million), 2019-2023

Figure 8-110: China – Annual Tresiba Sales (US\$ Million), 2019-2023
Figure 8-111: ROW – Annual Tresiba Sales (US\$ Million), 2019-2023
Figure 8-112: Global – Quarterly Tresiba Sales (US\$ Million), 2023
Figure 8-113: NA – Quarterly Tresiba Sales (US\$ Million), 2023
Figure 8-114: EMEA – Quarterly Tresiba Sales (US\$ Million), 2023
Figure 8-115: China – Quarterly Tresiba Sales (US\$ Million), 2023
Figure 8-116: ROW – Quarterly Tresiba Sales (US\$ Million), 2023
Figure 8-117: Global – Quarterly Tresiba Sales (US\$ Million), 2022
Figure 8-118: NA – Quarterly Tresiba Sales (US\$ Million), 2022
Figure 8-119: EMEA – Quarterly Tresiba Sales (US\$ Million), 2022
Figure 8-120: China – Quarterly Tresiba Sales (US\$ Million), 2022
Figure 8-121: ROW – Quarterly Tresiba Sales (US\$ Million), 2022
Figure 8-122: Rybelsus – Cost per Unit & Supply (US\$), November'2023
Figure 8-123: Global – Annual Rybelsus Sales (US\$ Million), 2019-2023
Figure 8-124: NA – Annual Rybelsus Sales (US\$ Million), 2019-2023
Figure 8-125: EMEA – Annual Rybelsus Sales (US\$ Million), 2019-2023
Figure 8-126: China – Annual Rybelsus Sales (US\$ Million), 2019-2023
Figure 8-127: ROW – Annual Rybelsus Sales (US\$ Million), 2019-2023
Figure 8-128: Global – Quarterly Rybelsus Sales (US\$ Million), 2023
Figure 8-129: NA – Quarterly Rybelsus Sales (US\$ Million), 2023
Figure 8-130: EMEA – Quarterly Rybelsus Sales (US\$ Million), 2023
Figure 8-131: China – Quarterly Rybelsus Sales (US\$ Million), 2023
Figure 8-132: ROW – Quarterly Rybelsus Sales (US\$ Million), 2023
Figure 8-133: Global – Quarterly Rybelsus Sales (US\$ Million), 2022
Figure 8-134: NA – Quarterly Rybelsus Sales (US\$ Million), 2022
Figure 8-135: EMEA – Quarterly Rybelsus Sales (US\$ Million), 2022
Figure 8-136: China – Quarterly Rybelsus Sales (US\$ Million), 2022
Figure 8-137: ROW – Quarterly Rybelsus Sales (US\$ Million), 2022
Figure 8-138: Xultophy – Cost per Unit & Supply (US\$), November'2023
Figure 8-139: Global – Annual Xultophy Sales (US\$ Million), 2019-2023
Figure 8-140: NA – Annual Xultophy Sales (US\$ Million), 2019-2023
Figure 8-141: EMEA – Annual Xultophy Sales (US\$ Million), 2019-2023
Figure 8-142: China – Annual Xultophy Sales (US\$ Million), 2019-2023
Figure 8-143: ROW – Annual Xultophy Sales (US\$ Million), 2019-2023
Figure 8-144: Global – Quarterly Xultophy Sales (US\$ Million), 2023
Figure 8-145: NA – Quarterly Xultophy Sales (US\$ Million), 2023
Figure 8-146: EMEA – Quarterly Xultophy Sales (US\$ Million), 2023
Figure 8-147: China – Quarterly Xultophy Sales (US\$ Million), 2023
Figure 8-148: ROW – Quarterly Xultophy Sales (US\$ Million), 2023

- Figure 8-149: Global – Quarterly Xultophy Sales (US\$ Million), 2022
- Figure 8-150: NA – Quarterly Xultophy Sales (US\$ Million), 2022
- Figure 8-151: EMEA – Quarterly Xultophy Sales (US\$ Million), 2022
- Figure 8-152: China – Quarterly Xultophy Sales (US\$ Million), 2022
- Figure 8-153: ROW – Quarterly Xultophy Sales (US\$ Million), 2022
- Figure 8-154: Victoza – Cost per Unit & Supply (US\$), November'2023
- Figure 8-155: Global – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-156: North America – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-157: EMEA – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-158: China – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-159: ROW – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-160: Global – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-161: North America – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-162: EMEA – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-163: China – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-164: ROW – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-165: Global – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-166: North America – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-167: EMEA – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-168: China – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-169: ROW – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-170: Global – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-171: EMEA – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-172: China – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-173: ROW – Annual Victoza Sales (US\$ Million), 2019-2023
- Figure 8-174: Global – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-175: EMEA – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-176: China – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-177: ROW – Quarterly Victoza Sales (US\$ Million), 2023
- Figure 8-178: Global – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-179: EMEA – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-180: China – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-181: ROW – Quarterly Victoza Sales (US\$ Million), 2022
- Figure 8-182: Fiasp – Cost per Unit & Supply (US\$), November'2023
- Figure 8-183: Global – Annual Fiasp Sales (US\$ Million), 2019-2023
- Figure 8-184: NA – Annual Fiasp Sales (US\$ Million), 2019-2023
- Figure 8-185: EMEA – Annual Fiasp Sales (US\$ Million), 2019-2023
- Figure 8-186: ROW – Annual Fiasp Sales (US\$ Million), 2019-2023
- Figure 8-187: Global – Quarterly Fiasp Sales (US\$ Million), 2023

- Figure 8-188: NA – Quarterly Fiasp Sales (US\$ Million), 2023
Figure 8-189: EMEA – Quarterly Fiasp Sales (US\$ Million), 2023
Figure 8-190: ROW – Quarterly Fiasp Sales (US\$ Million), 2023
Figure 8-191: Global – Quarterly Fiasp Sales (US\$ Million), 2022
Figure 8-192: NA – Quarterly Fiasp Sales (US\$ Million), 2022
Figure 8-193: EMEA – Quarterly Fiasp Sales (US\$ Million), 2022
Figure 8-194: ROW – Quarterly Fiasp Sales (US\$ Million), 2022
Figure 8-195: Lantus – Cost per Unit & Supply (US\$), November'2023
Figure 8-196: Insulin Glargine & Insulin Glargine-yfgn – Cost per Unit & Supply (US\$), November'2023
Figure 8-197: Global – Annual Lantus Sales (US\$ Million), 2019-2023
Figure 8-198: US – Annual Lantus Sales (US\$ Million), 2019-2023
Figure 8-199: Europe – Annual Lantus Sales (US\$ Million), 2019-2023
Figure 8-200: ROW – Annual Lantus Sales (US\$ Million), 2019-2023
Figure 8-201: Global – Quarterly Lantus Sales (US\$ Million), 2023
Figure 8-202: US – Quarterly Lantus Sales (US\$ Million), 2023
Figure 8-203: Europe – Quarterly Lantus Sales (US\$ Million), 2023
Figure 8-204: ROW – Quarterly Lantus Sales (US\$ Million), 2023
Figure 8-205: Global – Quarterly Lantus Sales (US\$ Million), 2022
Figure 8-206: US – Quarterly Lantus Sales (US\$ Million), 2022
Figure 8-207: Europe – Quarterly Lantus Sales (US\$ Million), 2022
Figure 8-208: ROW – Quarterly Lantus Sales (US\$ Million), 2022
Figure 8-209: Toujeo – US Patent Acceptance & Expiration Years
Figure 8-210: Toujeo – Cost per Unit & Supply (US\$), November'2023
Figure 8-211: Global – Annual Toujeo Sales (US\$ Million), 2019-2023
Figure 8-212: US – Annual Toujeo Sales (US\$ Million), 2019-2023
Figure 8-213: Europe – Annual Toujeo Sales (US\$ Million), 2019-2023
Figure 8-214: ROW – Annual Toujeo Sales (US\$ Million), 2019-2023
Figure 8-215: Global – Quarterly Toujeo Sales (US\$ Million), 2023
Figure 8-216: US – Quarterly Toujeo Sales (US\$ Million), 2023
Figure 8-217: Europe – Quarterly Toujeo Sales (US\$ Million), 2023
Figure 8-218: ROW – Quarterly Toujeo Sales (US\$ Million), 2023
Figure 8-219: Global – Quarterly Toujeo Sales (US\$ Million), 2022
Figure 8-220: US – Quarterly Toujeo Sales (US\$ Million), 2022
Figure 8-221: Europe – Quarterly Toujeo Sales (US\$ Million), 2022
Figure 8-222: ROW – Quarterly Toujeo Sales (US\$ Million), 2022
Figure 9-1: Biodrug Design Accelerator - Technical Benefits
Figure 9-2: Biodrug Design Accelerator - Technical Benefits
Figure 9-3: IO Biotech - T-win Technology

- Figure 9-4: Numatech – Numaferm Platform
- Figure 9-5: Nuritas - Scientific Achievements of Magnifier N?? Bioactive Peptide Discovery Platform
- Figure 9-6: Nuritas – The Magnifier N?? Bioactive Peptide Discovery Process
- Figure 9-7: Nuritas – The Magnifier N?? Bioactive Peptide Results
- Figure 9-8: GenScript - PepPower Technology
- Figure 9-9: PeptiDream – PDPS Outline
- Figure 9-10: PeptiDream – PDPS Outline
- Figure 9-11: PeptiDream – PDPS Features
- Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
- Figure 9-13: Veneno Technologies - Veneno Suite Components
- Figure 9-14: Veneno Technologies - Veneno Suite Process
- Figure 9-15: Peptron - SmartDepot™ Features
- Figure 9-16: Peptron - SmartDepot™ Manufacturing Scheme
- Figure 9-17: Bicycle Therapeutics – Bicycles Key Properties
- Figure 9-18: Bicycle Therapeutics – Bicycles Key Properties
- Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
- Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
- Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
- Figure 9-22: Benefits of Imotopes over Current Therapies
- Figure 9-23: Peptilogics – Peptide Development Process
- Figure 9-24: Peptilogics - Nautilus Features
- Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
- Figure 9-26: Cybrexa – alphalex Selective Tumor Cell Targeting

12. LIST OF TABLES

- Table 1- 1: Landmarks in Peptides Drugs Market
- Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
- Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
- Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum Calcium and Parathyroid Hormone Levels during Treatment
- Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
- Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
- Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged Years and Older
- Table 9-1: GenScript - PepPower™ Platform Advantages

I would like to order

Product name: Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029

Product link: <https://marketpublishers.com/r/G416833BDB0EEN.html>

Price: US\$ 5,100.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G416833BDB0EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970